Literature DB >> 20872318

The mechanism of action for oxyntomodulin in the regulation of obesity.

Katie Wynne1, Benjamin Ct Field, Stephen R Bloom.   

Abstract

Oxyntomodulin, a product of the proglucagon gene, is released from the enteroendocrine L-cells of the gastrointestinal tract after the digestion of food, and acts via glucagon-like peptide 1 receptors in the arcuate nucleus to induce satiety. The administration of oxyntomodulin to animals and humans causes weight loss by reducing food intake in combination with increasing energy expenditure. Thus, the development of potent and long-acting analogs of oxyntomodulin is an exciting new therapeutic avenue for addressing the global obesity epidemic. This review discusses the role of oxyntomodulin in the physiological control of appetite, and presents the currently available evidence suggesting its potential as an obesity treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872318

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  5 in total

1.  The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.

Authors:  Jennifer R Kosinski; James Hubert; Paul E Carrington; Gary G Chicchi; James Mu; Corey Miller; Jin Cao; Elisabetta Bianchi; Antonello Pessi; Ranabir Sinharoy; Donald J Marsh; Alessandro Pocai
Journal:  Obesity (Silver Spring)       Date:  2012-03-16       Impact factor: 5.002

Review 2.  Unraveling oxyntomodulin, GLP1's enigmatic brother.

Authors:  Alessandro Pocai
Journal:  J Endocrinol       Date:  2012-09-27       Impact factor: 4.286

3.  Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats.

Authors:  Elina Akalestou; Ioannis Christakis; Antonia M Solomou; James S Minnion; Guy A Rutter; Stephen R Bloom
Journal:  Pancreas       Date:  2016-08       Impact factor: 3.327

Review 4.  Proglucagon-Derived Peptides as Therapeutics.

Authors:  Ryan A Lafferty; Finbarr P M O'Harte; Nigel Irwin; Victor A Gault; Peter R Flatt
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-18       Impact factor: 5.555

Review 5.  Action and therapeutic potential of oxyntomodulin.

Authors:  Alessandro Pocai
Journal:  Mol Metab       Date:  2013-12-14       Impact factor: 7.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.